Log In Get Started
Press Releases April 14, 2026 04:15 PM

COMPX ANNOUNCES EXPECTED FIRST QUARTER 2026 EARNINGS RELEASE DATE

CompX International Inc. announces expected Q1 2026 earnings release date for May 5.

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
CIX

CompX International Inc., a manufacturer specializing in security products and recreational marine components, announced that it expects to release its first quarter 2026 earnings report on May 5, 2026, following the market close, pending the completion of quarter-end closing procedures.

COMPX ANNOUNCES EXPECTED FIRST QUARTER 2026 EARNINGS RELEASE DATE
CIX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CompX International is scheduled to report Q1 2026 earnings on May 5, 2026.
  • The company is a leading manufacturer in security products and recreational marine components.
  • The earnings report release is subject to usual quarter-end closing procedures.

Dallas, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- CompX International Inc. (NYSE American:  CIX) announced today that, subject to the completion of quarter-end closing procedures, it expects to report first quarter 2026 earnings in a press release after market close on Tuesday, May 5, 2026. 

CompX is a leading manufacturer of security products and recreational marine components.

* * * *

Investor Relations Contact

Bryan A. Hanley
Senior Vice President and Treasurer
Tel. 972-233-1700


Risks

  • Potential delays or adjustments in quarter-end closing procedures could affect earnings release timing.
  • Market conditions impacting manufacturing and demand for security and marine components.
  • Uncertainty in earnings performance which is not disclosed until the formal release date.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026